Molecule to Market: Inside the outsourcing space

The niche, niche CDMO with enviable patient reach

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jim Hall, President at Lifecore Biomedical

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jim, covering: 

• What a period working on the sponsor/buyer side taught him about getting best out of your CROs and CDMOs

• The challenges of doubling in size twice in just 10 years and not getting ‘too far out over your skis’
• Building a culture with longevity and not losing sight of the purpose - never hurting a patient
• Insight into market growth figures and why the injectable market remains a hot spot
• Timeless advice around not chasing the money, always be learning and keeping an open mind

Jim was appointed President in June 2017. He served as Vice President and General Manager since July 2013, Vice President of Operations since 2006 and was Director of Manufacturing Operations and Engineering since 2001; prior to that he was the Manager of Engineering and Operations at Lifecore. Mr. Hall brings over 30 years of pharmaceutical and combination product manufacturing and development experience.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

Diaries of DCAT

Last week marked the return of DCAT in New York City. A prestigious event that’s open to companies engaged in the Biotech and Pharmaceutical manufacturing space…

With the massive return this year of events. Your host, Raman Sehgal, decided to shake things up this year and do things differently, taking your favourite life science podcast Molecule to market with him… Equipped with only a laptop and a microphone, he hit the event space in style and interviewed some great guests along the way.

Listen to a variety of select guests at the top of their field. 

• Yasmin Davoodi, Head Of Commercial at ramarketing

• Jon Lenihan, Head of Sales & Business Development, CDMO Business Unit Head at Emergent Biosolutions

• David Enloe, President and CEO of Societal™ CDMO (formerly Recro)

• Gil Roth, President, Pharma and Biopharma Outsourcing Association

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

Finland’s Viral Vector Manufacturer of Happinesses

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Magnus Gustafsson, formerly at the time of recording Head of Global Business Development now Chief Business Officer at Biovian.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Magnus, covering:

• The advantages and disadvantages of viral vector products, including the challenge of needing to balance cost with patient access.

• Insights into a CDMO with a 96% staff retention rate and an enviable NPS score.

• The ballooning opportunity that exists in the viral vector space but also the risk that potentially comes along with such a popular platform.

• What makes Finland and the Nordic region so special?

Magnus Gustafsson has worked in the biopharma manufacturing space for over 20 years. He holds an MSc in Biochemical Engineering, an MBA in Business Administration and a PhD in Medical Protein Science. Having worked for the likes of AZ, GE, Recipharm and Cobra Biologics, he has a track record of driving business with both commercial and strategic success combined with a customer-centric mindset. 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

From corporate rebel to CDMO entrepreneur

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Hanns-Christian Mahler CEO at ten23 health.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Hanns, covering:

• Transitioning from the structure and scale of Merck, Roche and Lonza into an entrepreneurial start-up CDMO leader.
• Having a business purpose focused on the triple-bottom line that is not just profit - patients, people and planet.
• Tips and insights of how a CDMO can play its part in encouraging sustainability, reducing environmental impact and managing footprints, across all levels.
• Insights into the opportunity and growth in small-scale sterile biologics, and some of the drivers behind these trends.
• Dr. Mahler is CEO & Board Member at ten23 health. He previously led the Drug Product Services (DPS) Business Unit at Lonza and worked in various leadership roles at Roche and Merck. He has an extensive expertise in formulation development, process development & validation, packaging/device development and integration, sterile manufacturing, and regulatory submissions.

With a Ph.D. in toxicology, he also serves as Editor for Pharmaceutical Research, Journal of Pharmaceutical Sciences, AAPS Open Journal, and PDA Journal of Pharmaceutical Sciences & Technology. He has published more than 120 manuscripts and is co-inventor of more than 50 patents.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

Mr digital transformation

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with David Leitham, Senior Vice President and General Manager at Aspen Technology.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with David, covering:

• Why a transformative approach is now needed to better deal with new therapeutics and modalities.
• The pandemic as the inflexion point for companies in pharma to truly adapt technology and create a competitive advantage.
• How contract services organisations are driving change in the life science sector and why they could be the ‘lighthouse’ for others to follow.
• Being open to failure, embracing the wrong calls and treating every set back as a learning opportunity.

David leads the pharma business unit at AspenTech, defining solutions that best serve the needs of pharmaceutical manufacturers to accelerate digitalization in their environments.

Prior to AspenTech, David spent nearly 20 years with Thermo Fisher Scientific. 

He held multiple leadership positions, most recently as Vice President and General Manager responsible for a team of more than 500 people. In this role, he drove digital transformation efforts for multiple businesses within the company, while also integrating and harmonising product divisions for improved organisation and performance.

His previous roles include Glaxo SmithKline where he served as Vice President, Information Engineering, Technology and Architecture. David attended Penn State University where he holds a Master of Science degree in Software Engineering, and a Bachelor of Science degree in Aerospace Engineering.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

The Latin American logistics leader

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jaqueline Escotero, Regional Vice President for Latin America at World Courier.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jaqueline, covering:

• The misconnections, characteristics and challenges of doing business in Latin America’s pharmaceutical sector.
• The immense complexity and level of responsibility involved in vaccine storage and distribution over the last year.
• Timeless lessons from a lifetime spent doing international business all over the world.
• A key trend that everyone in our sector needs to be prepared for in a post-pandemic world.

Jaqueline is responsible for the World Courier business in Latin America and is based in São Paulo, Brazil. She is an experienced executive, with 29 years of international experience in the healthcare industry, leading important roles in marketing, sales, training, government and external affairs, specialty logistics and customer service at major pharmaceutical and medical device companies. She holds an MBA in Strategic Marketing and Bachelor Degree in International Business. She is also the global Chairperson of WIN - “Women’s Impact Network” - at AmerisourceBergen, a global initiative, focused on over 40,000 employees.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

We are also proudly supported by Zymewire, which is the leader in actionable sales intelligence for life science Business development professionals. In fact, thousands of life science BD professionals start their day with sales signals from Zymewire. Learn more at tryzymewire.com

 

The opportunistic entrepreneur

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Ross Burn, Chief Executive at CatSci.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Ross, covering:

• Creating a successful business from an opportunistic AZ spin-out.
• Never being afraid to pivot in-line with the needs of the market and have big aims like becoming an innovative medicines development partner with a $1 billion valuation.
• The challenge of raising capital as an oversubscribed CRO with a 50% compound growth rate.

How the pandemic has helped put life sciences and pharma R&D on the map but also the work to be done to meet unmet needs.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

We are also proudly supported by Zymewire, which is the leader in actionable sales intelligence for life science Business development professionals. In fact, thousands of life science BD professionals start their day with sales signals from Zymewire. Learn more at tryzymewire.com

The Floundering Founder, a lifetime of knowledge for as little as a pound/dollar.

In this special bonus episode of Molecule to Market, our host discusses his very first book launch ‘The Floundering Founder’ which is now available on Amazon and Kindle. 

Whilst you know him as the host of Molecule to Market, Raman has built up an impressive career in marketing, leadership and sector disciplines over the past 20+ years working within the global pharmaceutical and biotech outsourcing sector. Over the past twelve months of that career, Raman has spent an hour each day working on his latest achievement: ‘The Floundering Founder.’

The Floundering Founder gives 24 lessons to refocus your business and better yourself.  

With quick, simple lessons, The Floundering Founder can help you re-engineer your business and your life for sustainable, long-term success.

In twenty-four bite-sized lessons that fit any schedule, you’ll learn to navigate forward with renewed intentionality and purpose.

Make no mistake, this book isn’t fictional. You will relive the close and personal revelations of starting and scaling a business and how ramarketing has grown to be one of the most fast-growing global marketing agencies. 

To purchase visit:

UK link is here

US link is here

We would love to hear what you think of the book! Please write us a review to let us know what you think in the review section.

From Pharmacy to $1B family-owned CDMO

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Peter Soelkner, Managing Director at Vetter.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Peter, covering:

• The fascinating and humble origin story of one of the world’s most well respected sterile filling specialists.
• Peter’s journey of leading Vetter in becoming a $1bn, 5500 person family-owned CDMO...alongside a fellow Managing Director.
• How the DNA of a culture becomes a critical competent of global business growth and consistent client delivery.
• Key future industry trends, including the challenge of preparing for the ‘colourful scenery of biotechs in the next 10 years’ - meaning the need to have the flexibility to deal with ultra orphan drug products and high volume products needing high speed lines.

Peter Soelkner has been a Managing Director of Vetter Pharma-Fertigung GmbH & Co. KG since June 2008. In 2009, he was also appointed Managing Director of Vetter Pharma International GmbH, the company’s marketing and sales organization. Soelkner graduated from the University of Dortmund, Germany, in 1992 with a degree in chemical engineering and earned an MBA from Columbia University, New York, in 2001. Before joining Vetter, he held positions in Germany and North America at Sartorius AG and Sartorius North America Inc., in R&D, marketing, key account management, and general management roles. At Vetter, from 2003 to 2007, Soelkner managed the company’s key account program and global end-to-end supply chain. He left the company for a year to serve as Vice President of global key account management at Sartorius Stedim Biotech (USA) before returning to Vetter in 2008.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

We are also proudly supported by Zymewire, which is the leader in actionable sales intelligence for life science Business development professionals. In fact, thousands of life science BD professionals start their day with sales signals from Zymewire. Learn more at tryzymewire.com

Roundtable: M&A trends in CDMO

In this special roundtable episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with:

Jean-Jacques Mondoloni, Managing Partner WOMBAT CAPITAL

Mark Quick, Executive Vice President Corporate Development at Recipharm

Gerry Cox, Vice President at Pace Life Sciences

Your host, Raman Sehgal, discusses M&A trends in the pharmaceutical and biotechnology supply chain, covering:

• What a real-life M&A deal in outsourcing looks like from the buyer, seller and advisor angle.
• How the dynamics of M&A have changed over the last decade given the fragmented marketplace alongside increased funding, PE-interest and a pandemic spotlight now on the sector.
• Dizzying multiples, the fight for assets and key factors driving deals and valuations in contract services.
• Predictions from the panel around the future of deal flow in the outsourcing space... will the current velocity continue?

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

We are also proudly supported by Zymewire, which is the leader in actionable sales intelligence for life science Business development professionals. In fact, thousands of life science BD professionals start their day with sales signals from Zymewire. Learn more at tryzymewire.com